Farrerol

Farrerol

SCHEMBL928045

Cc1c(O)c(C)c2c(c1O)C(=O)CC(c1ccc(O)cc1)O2

nearest known ligand 0.80

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 8/20 0.71
ESR2 Q92731 8/20 0.71
MEN1 O00255 2/20 0.64
POLB P06746 2/20 0.64
KMT2A Q03164 2/20 0.64
APEX1 P27695 1/20 0.64
RECQL P46063 1/20 0.64
CACNA1B Q00975 1/20 0.64
APBA1 Q02410 1/20 0.64
MCL1 Q07820 1/20 0.64
CTDSP1 Q9GZU7 1/20 0.64
L3MBTL1 Q9Y468 1/20 0.64
MAPT P10636 1/20 0.57
XBP1 P17861 1/20 0.57
GUSB P08236 4/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11120379 0.89 ESR1 (0.57) ESR1ESR2MEN1POLBKMT2A
Demethoxymatteucinol SCHEMBL29204370 0.89 ABCG2 (0.64) ESR1ESR2MEN1POLBKMT2A
Demethoxymatteucinol SCHEMBL664144 0.89 ABCG2 (0.64) ESR1ESR2MEN1POLBKMT2A
SCHEMBL7543177 0.87 CYP1A1 (0.57) ESR1ESR2MEN1POLBKMT2A
SCHEMBL29776987 0.87 CYP1A1 (0.57) ESR1ESR2MEN1POLBKMT2A
SCHEMBL1201860 0.87 ESR1 (0.55) ESR1ESR2MEN1POLBKMT2A
SCHEMBL1200443 0.87 ESR1 (0.55) ESR1ESR2MEN1POLBKMT2A
Cyrtominetin SCHEMBL1201687 0.85 POLB (0.62) ESR1ESR2MEN1POLBKMT2A
Cyrtominetin SCHEMBL29657275 0.85 POLB (0.62) ESR1ESR2MEN1POLBKMT2A
Cyrtominetin SCHEMBL30846161 0.85 POLB (0.62) ESR1ESR2MEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115058451-B Double-report plasmid for homologous recombination and single-base editing, and construction method and application thereof 五邑大学 2025-01-07 CN claimed
CN-118480578-A Nucleic acid molecule, cell line, construction method and detection method for detecting NHEJ repair and HDR repair in CRISPR-Cas gene editing 苏州金唯智生物科技有限公司 2024-08-13 CN claimed
CN-116694560-A Culture medium containing azalea essence and SCR7 for improving developmental defect of somatic cell nuclear transfer embryo and application thereof 上海市第一妇婴保健院 2023-09-05 CN claimed
CN-116042513-A Culture medium containing azalea essence for improving developmental defect of somatic cell nuclear transfer embryo and application thereof 上海市第一妇婴保健院 2023-05-02 CN claimed
CN-110372767-B Method for extracting and separating white rhododendron from rhododendron roseum leaves 西北师范大学 2023-03-24 CN claimed
CN-113087749-B Novel farrerol glycoside free radical inhibitor in saxifrage tangutica, and separation preparation process and application thereof 中国科学院西北高原生物研究所 2023-03-10 CN claimed
CN-115501223-A Application of farrerol in preparation of medicine for resisting cerebral ischemia reperfusion injury 青岛大学 2022-12-23 CN claimed
CN-115501222-A Application and method of farrerol for promoting somatic cell nuclear transfer efficiency 同济大学 2022-12-23 CN claimed
CN-113417055-B Interwoven fabric of cotton fiber, spandex fiber and polyester fiber and production method 衣拉拉集团股份有限公司 2022-11-04 CN claimed
CN-114848544-A Skin care product for repairing skin after being exposed to sun and preparation method thereof 胡亮亮 2022-08-05 CN claimed
CN-101384246-A External preparation for skin containing flavanone derivative POLA CHEM IND INC (JP) 2009-03-11 CN claimed
US-20090030070-A1 EXTERNAL PREPARATION FOR SKIN CONTAINING FLAVANONE DERIVATIVE POLA CHEMICAL INDUSTRIES INC. 2009-01-29 US claimed
EP-1987810-A1 EXTERNAL PREPARATION FOR SKIN CONTAINING FLAVANONE DERIVATIVE Pola Chemical Industries Inc. (JP) 2008-11-05 EP claimed
CN-101066245-A Orally taken emulsion and its prepn ZHU FANGHAI (CN) 2007-11-07 CN claimed
CN-1634324-A Dahurian rhododendron leaf extract and extracting method thereof LI QINGSHAN (CN) 2005-07-06 CN claimed
CN-1370527-A Toxoprotein, medicament for toxoprotein caused disease and the disease preventing and treating method CHEN JIANCAO (CN) 2002-09-25 CN claimed
CN-1228976-A Compound cordyceps sinensis cough and asthma syrup LI KEQIANG (CN) 1999-09-22 CN claimed
CN-1191130-A Anti-AIDS virus, anti-Treponema pallidum, anti-gonococcus, anti-candida albicans and anti-trichomonas natural drug LEI XUEJUN (CN) 1998-08-26 CN claimed
CN-1124653-A Natural medicine for resisting pyloric Helicobacterium LEI XUEJUN (CN) 1996-06-19 CN claimed
EP-0122053-A2 Pharmaceutical compositions containing compounds with a flavanone skeleton and process for the preparation of said compounds INVERNI DELLA BEFFA S.P.A. (IT) 1984-10-17 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030070-A1 EXTERNAL PREPARATION FOR SKIN CONTAINING FLAVANONE DERIVATIVE COL14A1, FIBP, COL1A1 ESR1 2928/4885ESR2 2675/4885MEN1 4555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.